Meeting
2016 ASCO Annual Meeting
Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?
Authors
Clara Inkyung Lee
Westmead Hospital, Sydney, Australia
Clara Inkyung Lee , Amanda Siew Kee Low , Peter Fox , Bavanthi Balakrishnar , Rosemary L Balleine , Bo Gao , Pamela Provan , Sally Coulter , Christopher Liddle , Rina Hui , Nicholas Wilcken , Mark Wong , Howard Gurney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 536)
DOI
10.1200/JCO.2016.34.15_suppl.536
Abstract #
536
Poster Bd #
24
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1.
First Author: Toshimi Takano
Poster
2018 ASCO Annual Meeting
Impact of curcumin with and without (+/-) piperine on tamoxifen exposure.
First Author: Gerardus Hussaarts
Poster
2016 ASCO Annual Meeting
Comparison of endoxifen levels between male and female breast cancer patients treated with tamoxifen.
First Author: John Gordon Lenehan
Poster
2012 ASCO Annual Meeting
CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.
First Author: Bavanthi Balakrishnar